Olanzapine
SGA • Brands: Zyprexa
Last reviewed: 2025-09-23
General information
Indicated for: Olanzapine for Injection is an atypical antipsychotic indicated for the: Treatment of acute agitation associated with schizophrenia and bipolar I mania. ( 1.4 ) Efficacy was established in three 1-day trials in adults. ( 14.3 ) Efficacy was established in three 1-day trials in adults. ( 14.3 )
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: 10–20 mg/day
Mechanism (brief)
Antagonist at 5-HT2A and D2; strong H1 and muscarinic activity.
Metabolism & Half‑life
- Metabolism: Hepatic (CYP1A2, minor 2D6), smoking induces clearance.
- Half‑life: ~30 h (range ~20–54 h).
Therapeutic Drug Monitoring (TDM)
Recommended: No
View labelExact
Long‑acting injectable (LAI)
Monitoring highlights
- Metabolic: weight, BMI, fasting lipids/glucose — Baseline, 3 mo, annually
In‑depth reading
- Comparative effects of 18 antipsychotics on metabolic function in schizophrenia: systematic review and network meta-analysis. — The Lancet Psychiatry (2020)
- Metabolic effects of olanzapine: systematic review — Systematic review (2019)
- Olanzapine/fluoxetine for bipolar depression: randomized trials — RCTs (2016)
Sources
- Olanzapine label — DailyMed (2025)